
SYRE
Healthcare · Biotechnology · $9.88B market cap
$104.00+1.09 (+1.1%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -17.9% over 90 days · 30-day revisions 4 up, 7 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2026 | After the close | -0.79 | -0.94 | -19.0% |
| Aug 4, 2026 | After the close | -0.71 | -0.36 | +49.3% |
| May 7, 2026 | Time not confirmed | -0.64 | -0.74 | -14.8% |
| Feb 19, 2026 | After the close | -0.80 | -0.74 | +7.5% |
| Nov 4, 2025 | After the close | -0.74 | -0.15 | +79.7% |
| Aug 5, 2025 | After the close | -0.71 | -0.49 | +31.0% |
| May 8, 2025 | After the close | -0.84 | -0.60 | +28.6% |
| Feb 26, 2025 | After the close | -0.94 | -0.81 | +14.2% |
| Nov 7, 2024 | After the close | -0.86 | -1.36 | -58.1% |
| Aug 7, 2024 | After the close | -0.91 | -0.86 | +5.5% |
| May 9, 2024 | After the close | -1.08 | -1.20 | -11.1% |
| Feb 29, 2024 | After the close | -0.78 | -4.05 | -419.2% |
| Nov 9, 2023 | After the close | -0.84 |
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's…
| -9.34 |
| -1011.9% |
| Aug 11, 2023 | Before the open | -3.50 | -56.75 | -1521.4% |
| May 11, 2023 | Before the open | -4.37 | -5.00 | -14.4% |
| Mar 2, 2023 | Time not confirmed | -0.23 | -5.00 | -2090.1% |
| Nov 3, 2022 | Before the open | -5.87 | -4.75 | +19.1% |
| Aug 4, 2022 | Before the open | -7.75 | -6.75 | +12.9% |
| May 5, 2022 | Time not confirmed | -0.34 | -9.25 | -2609.4% |
| Mar 8, 2022 | Before the open | -7.63 | -7.75 | -1.6% |
| Nov 4, 2021 | Before the open | -7.34 | -7.75 | -5.6% |
| Aug 5, 2021 | Before the open | -4.30 | -2.50 | +41.9% |
| May 10, 2021 | Before the open | -3.49 | -7.00 | -100.6% |
| Mar 18, 2021 | Time not confirmed | -0.34 | -8.75 | -2451.8% |
| Nov 5, 2020 | Before the open | -9.97 | -7.25 | +27.3% |
| Aug 10, 2020 | Before the open | -10.76 | -10.00 | +7.1% |
| May 7, 2020 | Before the open | -16.41 | -14.25 | +13.2% |
| Feb 24, 2020 | Time not confirmed | -0.67 | -16.25 | -2325.4% |
| Nov 6, 2019 | Before the open | -13.31 | -16.50 | -24.0% |
| Aug 6, 2019 | Before the open | -12.08 | -13.75 | -13.8% |
| May 7, 2019 | Before the open | -13.80 | -14.75 | -6.9% |
| Mar 7, 2019 | Time not confirmed | -0.37 | -15.50 | -4089.2% |
| Nov 8, 2018 | Before the open | -10.80 | -13.50 | -25.0% |
| Aug 9, 2018 | Before the open | -8.62 | -11.50 | -33.4% |
| May 8, 2018 | Before the open | -11.51 | -12.25 | -6.4% |
| Mar 13, 2018 | Time not confirmed | -0.53 | -9.75 | -1739.6% |